Anti-cancer coating compositions comprising 3-hydroxymethyl-5-aziridinyl-1-1-methyl-2-[1H-indole-4,7-dione]propenol
(E09) are disclosed. More specifically, the coating compositions comprise EO9 and
a formulation vehicle. The formulation vehicle improves the solubility and stability
of EO9. Additionally, the coating compositions can include coating agents that
provide better adhesion of the coating composition to the bladder wall during intravesical
delivery of the coating composition.
